Sangamo is using groundbreaking science and novel technology to replace today’s symptomatic treatments with tomorrow’s genomic cures

Mom Daughter hugging

We are pursuing programs across the spectrum of genomic medicine, with gene and cell therapies in the clinic today and preclinical programs in genome engineering and off-the-shelf cell therapy. Behind these are research efforts thoughtfully focused on leveraging our differentiated zinc finger technology. We are advancing a robust pipeline of wholly owned and partnered programs in rare disease, neurology, oncology and autoimmune indications with the goal of developing genomic medicines that transform the lives of patients.

Our Pipeline

Phase 3
  • Hemophilia A

    Giroctocogene Fitelparvovec

    Sangamo Logo
    |
  • Gene therapy
  • Cell therapy
  • Genome engineering
Learn more about our clinical trials
Phase 1/2
  • Fabry Disease

    Isaralgagene civaparvovec

    Sangamo Logo
  • Renal Transplant

    TX200

    Sangamo Logo
  • Sickle Cell Disease

    SAR445136

    Sangamo Logo
    |
Preclinical
  • Inflammatory Bowel Disease
    Sangamo Logo
  • Renal Transplant

    (Allogeneic)

    Sangamo Logo
  • Multiple Sclerosis
    Sangamo Logo
  • Prion
    Sangamo Logo
  • Neurology

    Undisclosed

    Sangamo Logo
  • Oncology

    KITE-037

    Sangamo Logo
    |
  • Oncology

    Undisclosed

    Sangamo Logo
    |
  • Neuro- developmental Disorders
    Sangamo Logo
    |
  • ALS/FTD
    Sangamo Logo
    |
  • Huntington’s Disease

    TAK-686

    Sangamo Logo
    |
  • a-Synuclein

    ST-502

    Sangamo Logo
    |
  • Tauopathies

    ST-501

    Sangamo Logo
    |
  • Neurology

    DMI

    Sangamo Logo
    |
  • Neurology

    Undisclosed

    Sangamo Logo
    |

Collaborations

We seek collaborations that can extend or complement our leading genomic medicine capabilities

Sangamo’s novel technology and depth of scientific expertise make us a partner of choice among leading global pharmaceutical companies. Whether through in-licensing, out-licensing, scientific collaborations or advancing our corporate development priorities, our collaborations extend the reach of our technology and accelerate the development of genomic medicines. These are some of the ways we deliver on our commitment to get new treatments to patients in need.


Our Partners

Image: Biogen Logo

Biogen and Sangamo have a global licensing collaboration agreement to develop and commercialize ST-501 for tauopathies including Alzheimer’s disease, ST-502 for synucleinopathies including Parkinson’s disease, a third undisclosed neuromuscular disease target, and up to nine additional undisclosed neurological disease targets.

Image: Kite Logo

Kite, a Gilead Company, and Sangamo are developing next-generation ex vivo cell therapies to treat cancer by using Sangamo’s zinc finger nuclease (ZFN) technology.

Image: Mogrify Logo

Mogrify and Sangamo have a collaboration and exclusive license agreement providing Sangamo with access to Mogrify’s cell conversion reprogramming technology, which Sangamo expects will accelerate its development of scalable and accessible CAR-Treg cell therapies.

Image: Novartis Logo

Novartis and Sangamo have a global licensing collaboration agreement to develop and commercialize gene regulation therapies to address neurodevelopmental targets, including genes linked to autism spectrum disorder and other neurodevelopmental disorders.

Image: Pfizer Logo

Pfizer and Sangamo have an exclusive, global collaboration and license agreement to develop and commercialize gene therapies for hemophilia. Sangamo and Pfizer are also collaborating for the development and commercialization of therapeutics using our zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.

Image: Sanofi Logo

Sanofi and Sangamo are developing gene-edited cell therapy for the treatment of sickle cell disease, using Sangamo’s zinc finger nuclease technology.

Image: Takeda Logo

Takeda and Sangamo are developing therapeutics for Huntington's disease utilizing our ZFP-TF genome regulation platform.

Interested in collaborating with us?

Contact Mark McClung, Executive Vice President, Chief Operating Officer

Contact Mark